

Table 1: Classification of papers according to regression models (Cox, cause-specific, or Fine and Gray and logistic) used to investigate risk factors of time-to-event outcomes.

| Outcome investigated | Regression model mentioned | References |
|--|-----------------------------------|---|
| Exactly known time-to-event | | |
| All-cause death | Cox model | [13, 17, 36, 63-167] |
| | Cause-specific model | [8, 13, 79, 168-174] |
| | Fine and Gray model | [8, 14, 36, 69, 80, 152, 169, 171, 175, 176] |
| | Logistic model | [177-180] |
| Cardiovascular death | Cox model | [70, 72, 74, 77, 91, 93, 95-97, 115, 122, 124-129, 132, 135, 147, 151, 156, 164, 167, 181-185] |
| | Cause-specific model | [186] |
| | Fine and Gray model | [175] |
| Cardiovascular event | Cox model | [71, 78, 83, 95, 115, 135, 139, 148, 164, 165, 187-199] |
| Initiation of kidney replacement therapy or death due to kidney failure | Cox model | [64, 65, 68, 74, 76, 78, 81, 87-89, 91, 95-97, 102, 112, 114, 116, 118, 120, 130, 131, 140, 142, 143, 145, 152, 155, 161, 162, 188, 189, 200-232] |
| | Fine and Gray model | [8, 14, 69, 80, 136, 152, 169, 175, 176, 210] |
| | Cause-specific model | [8, 13, 79, 169, 172, 173, 228] |
| | Logistic model | [233] |
| Initiation of kidney replacement therapy or death (whichever comes first) | Cox model | [17, 37, 69, 74, 88, 90, 96, 97, 102, 103, 105, 106, 108, 112-114, 124, 129, 143, 167, 215, 217, 220, 225-227, 232, 234-244] |
| Interval-censored time-to-event | | |
| Absolute or relative change in renal function higher than a specific value as compared to baseline value, based on - GFR - creatinine clearance - proteinuria | Cox model | [36, 163, 245-249] |
| | Fine and Gray model | [36] |
| | Logistic model | [89, 169, 213, 250-257] |
| Transition to a specific stage of disease (based on CKD or proteinuria) | Cox model | [9, 92, 146, 235, 245, 258-261] |
| | Logistic model | [262-265] |
| Doubling of creatinine (serum or clearance) | Cox model | [130, 131, 211, 266-269] |
| | Logistic model | [270] |
| Composite of exact and interval-censored time-to-events | Cox model | [36, 63, 78, 83, 141, 148, 153, 190, 192, 194, 201, 209, 211, 238, 271-291] |
| | Fine and Gray model | [36, 171, 292] |
| | Cause-specific model | [168, 170, 171] |
| | Logistic model | [179, 293] |

Abbreviations: GFR, glomerular filtration rate; CKD, chronic kidney disease

Table 2: Classification of papers according to regression models (standard linear or linear mixed model, and generalized estimating equations) used to investigate repeated measurements of renal function.

| Outcome investigated | Regression model mentioned | References |
|---|--|--|
| All repeated measurements of renal function | | |
| Repeated measurements of - GFR - Creatinine clearance - Proteinuria | Linear mixed model | [17, 36, 37, 41, 55, 56, 236, 292, 294-307] |
| | Linear mixed model accounting for informative drop-out | [55-58, 107, 170, 297, 308, 309] |
| | Linear GEE | [216, 291, 295, 310] |
| | Linear GEE accounting for informative drop-out | [311] |
| | Latent class growth analysis | [45] |
| Repeated measurements of - log GFR - log creatinine (serum or clearance) - log proteinuria | Linear mixed model | [9, 140, 260, 312-314] |
| | Linear GEE | [38, 84] |
| | Latent class growth analysis | [9] |
| Absolute GFR change between each visit and baseline | Linear mixed model | [299] |
| Relative GFR change each year | Linear GEE | [163] |
| A summary statistic for the change of renal function | | |
| Individual slope of - GFR - Creatinine (serum or clearance) - UACR | Linear model | [37, 69, 96, 97, 118, 204, 224, 240, 246, 251, 252, 254, 267, 273, 278, 315-331] |
| | Linear model | [81, 245, 255, 262, 332-334] |
| | Linear model | [81] |
| Log of absolute proteinuria change as compared to baseline | Linear model | [245] |

Abbreviations: GFR, glomerular filtration rate; GEE, generalized estimating equations; UACR, urine albumin-to-creatinine ratio

^a Slope of a marker is a summary statistic derived from measurements of a patient

Papers that investigated outcomes that are not mentioned in Table 1 and 2: [18, 29, 335-350].

8. Lim HJ, Zhang X, Dyck R, Osgood N: **Methods of Competing Risks Analysis of End-Stage Renal Disease and Mortality among People with Diabetes.** *BMC Med Res Methodol* 2010, **10**:97.
9. De Beaudrap P, Diallo MB, Landman R, Gueye NF, Ndiaye I, Diouf A, Kane CT, Etard JF, Girard PM, Sow PS, Delaporte E: **Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).** *AIDS Res Hum Retroviruses* 2010, **26**:1221-1227.
13. De Nicola L, Minutolo R, Chiodini P, Zamboli P, Cianciaruso B, Nappi F, Signoriello S, Conte G, Zoccali C, Group S-TCS: **Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics.** *Am J Nephrol* 2010, **32**:533-540.
14. Forsblom C, Harjutsalo V, Thorn LM, Waden J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH: **Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria.** *J Am Soc Nephrol* 2011, **22**:537-544.
17. Cianciaruso B, Pota A, Bellizzi V, Di Giuseppe D, Di Micco L, Minutolo R, Pisani A, Sabbatini M, Ravani P: **Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial.** *Am J Kidney Dis* 2009, **54**:1052-1061.
18. Scolari F, Ravani P, Gaggi R, Santostefano M, Rollino C, Stabellini N, Colla L, Viola BF, Maiorca P, Venturelli C, et al: **The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors.** *Circulation* 2007, **116**:298-304.
29. Hu B, Li L, Wang X, Greene T: **Nonparametric multistate representations of survival and longitudinal data with measurement error.** *Stat Med* 2012, **31**:2303-2317.
36. Alves TP, Hulgán T, Wu P, Sterling TR, Stinnette SE, Rebeiro PF, Vincz AJ, Bruce M, Ikizler TA: **Race, kidney disease progression, and mortality risk in HIV-infected persons.** *Clin J Am Soc Nephrol* 2010, **5**:2269-2275.
37. Evans M, Fore D, Bellocco R, Fitzmaurice G, Fryzek JP, McLaughlin JK, Nyren O, Elinder CG: **Acetaminophen, aspirin and progression of advanced chronic kidney disease.** *Nephrol Dial Transplant* 2009, **24**:1908-1918.
38. Agarwal M, Selvan V, Freedman BI, Liu Y, Wagenknecht LE: **The relationship between albuminuria and hormone therapy in postmenopausal women.** *Am J Kidney Dis* 2005, **45**:1019-1025.
41. Ishwaran H, Takahara G: **Independent and identically distributed Monte Carlo algorithms for semiparametric linear mixed models.** *J Am Stat Assoc* 2002, **97**:1154-1166.
45. O'Hare AM, Batten A, Burrows NR, Pavkov ME, Taylor L, Gupta I, Todd-Stenberg J, Maynard C, Rodriguez RA, Murtagh FE, et al: **Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis.** *Am J Kidney Dis* 2012, **59**:513-522.
55. Eriksen BO, Tomtum J, Ingebretsen OC: **Predictors of declining glomerular filtration rate in a population-based chronic kidney disease cohort.** *Nephron Clin Pract* 2010, **115**:c41-50.
56. Fung MM, Salem RM, Lipkowitz MS, Bhatnagar V, Pandey B, Schork NJ, O'Connor DT: **Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC).** *Nephrol Dial Transplant* 2012, **27**:197-205.
57. Li J, Schluchter MD: **Conditional mixed models adjusting for non-ignorable drop-out with administrative censoring in longitudinal studies.** *Stat Med* 2004, **23**:3489-3503.
58. Vonesh EF, Greene T, Schluchter MD: **Shared parameter models for the joint analysis of longitudinal data and event times.** *Stat Med* 2006, **25**:143-163.
63. Agarwal R: **Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease.** *Clin J Am Soc Nephrol* 2009, **4**:830-837.
64. Agarwal R, Debella YT, Giduma HD, Light RP: **Long-term retinal, renal and cardiovascular outcomes in diabetic chronic kidney disease without proteinuria.** *Nephrol Dial Transplant* 2012, **27**:310-317.
65. Agarwal R, Kariyanna SS, Light RP: **Prognostic value of circadian blood pressure variation in chronic kidney disease.** *Am J Nephrol* 2009, **30**:547-553.
66. Ahmed A, Love TE, Sui X, Rich MW: **Effects of Angiotensin-Converting Enzyme Inhibitors in Systolic Heart Failure Patients With Chronic Kidney Disease: A Propensity Score Analysis.** *J Card Fail* 2006, **12**:499-506.

67. Al-Aly Z, Zeringue A, Fu J, Rauchman MI, McDonald JR, El-Achkar TM, Balasubramanian S, Nurutdinova D, Xian H, Stroupe K, et al: **Rate of kidney function decline associates with mortality.** *J Am Soc Nephrol* 2010, **21**:1961-1969.
68. Astor BC, Matsushita K, Gansevoort RT, Van Der Velde M, Woodward M, Levey AS, Jong PED, Coresh J, El-Nahas M, Eckardt KU, et al: **Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.** *Kidney Int* 2011, **79**:1331-1340.
69. Barbour SJ, Er L, Djurdjev O, Karim MM, Levin A: **Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients.** *Nephrol Dial Transplant* 2010, **25**:3663-3672.
70. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA: **Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.** *Clin J Am Soc Nephrol* 2009, **4**:1551-1558.
71. Beddhu S, Nigwekar SU, Ma X, Greene T: **Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease.** *Nephrol Dial Transplant* 2009, **24**:2482-2488.
72. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, et al: **Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease findings from propensity-matched studies.** *Circ Heart Fail* 2010, **3**:253-260.
73. Breton G, Froissart M, Janus N, Launay-Vacher V, Berr C, Tzourio C, Helmer C, Stengel B: **Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function-the Three-City population-based study.** *Nephrol Dial Transplant* 2011, **26**:2852-2859.
74. Chawla V, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V: **Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease.** *Clin J Am Soc Nephrol* 2010, **5**:1582-1587.
75. Chen JLT, Lerner D, Ruthazer R, Castaneda-Sceppa C, Levey AS: **Association of physical activity with mortality in chronic kidney disease.** *J Nephrol* 2008, **21**:243-252.
76. Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD: **Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan.** *Nephron Clin Pract* 2008, **109**:c109-c118.
77. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: **Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.** *Lancet* 2010, **375**:2073-2081.
78. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JFE: **Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: A cohort study.** *Ann Intern Med* 2011, **154**:310-318.
79. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Lorio BD, Santoro D, Giancaspro V, Abaterusso C, Gallo C, et al: **Prognosis of CKD patients receiving outpatient nephrology care in Italy.** *Clin J Am Soc Nephrol* 2011, **6**:2421-2428.
80. De Nicola L, Minutolo R, Chiodini P, Borrelli S, Zoccali C, Postorino M, Iodice C, Nappi F, Fuiano G, Gallo C, Conte G: **The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care.** *Kidney Int* 2012, **82**:482-488.
81. Dichtel LE, Gurevich DF, Rifkin B, Varma P, Concato J, Peixoto AJ: **Renal artery revascularization in patients with atherosclerotic renal artery stenosis and impaired renal function: Conservative management versus renal artery stenting.** *Clin Nephrol* 2010, **74**:113-122.
82. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, Hegarty J, New J, O'Donoghue DJ, Middleton RJ, Kalra PA: **Serum phosphate and mortality in patients with chronic kidney disease.** *Clin J Am Soc Nephrol* 2010, **5**:2251-2257.
83. Fischer MJ, Kimmel PL, Greene T, Gassman JJ, Wang X, Brooks DH, Charleston J, Dowie D, Thornley-Brown D, Cooper LA, et al: **Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease.** *Kidney Int* 2011, **80**:670-678.
84. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CCJ, Rompalo AM, Schuman P, Klein RS: **Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women.** *J Acquir Immune Defic Syndr* 2003, **32**:203-209.
85. Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Aragoncillo I, Verdalles U, Mosse A, Luño J: **Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4.** *Kidney Int Suppl* 2008:S67-70.
86. Hartle JE, Tang X, Kirchner HL, Bucaloiu ID, Sartorius JA, Pogrebnaya ZV, Akers GA, Carnero GE, Perkins RM: **Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: A retrospective cohort study.** *Am J Kidney Dis* 2012, **59**:636-644.

87. Haynes R, Hutchison CA, Emberson J, Dasgupta T, Wheeler DC, Townend JN, Landray MJ, Cockwell P: **Serum free light chains and the risk of ESRD and death in CKD.** *Clin J Am Soc Nephrol* 2011, **6**:2829-2837.
88. Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, Foley RN, Middleton RJ: **Factors associated with kidney disease progression and mortality in a referred CKD population.** *Am J Kidney Dis* 2010, **56**:1072-1081.
89. Hossain MP, Palmer D, Goyder E, El Nahas AM: **Association of deprivation with worse outcomes in chronic kidney disease: Findings from a Hospital-Based Cohort in the United Kingdom.** *Nephron Clin Pract* 2012, **120**:c59-c70.
90. Hovind P, Tarnow L, Rossing P, Carstensen B, Parving HH: **Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.** *Kidney Int* 2004, **66**:1180-1186.
91. Hwang SJ, Lin MY, Chen HC, Hwang SC, Yang WC, Hsu CC, Chiu HC, Mau LW: **Increased risk of mortality in the elderly population with late-stage chronic kidney disease: A cohort study in Taiwan.** *Nephrol Dial Transplant* 2008, **23**:3192-3198.
92. Ishani A, Nelson D, Clothier B, Schult T, Nugent S, Greer N, Slinin Y, Ensrud KE: **The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death.** *Arch Intern Med* 2011, **171**:226-233.
93. Ix JH, Shlipak MG, Sarnak MJ, Beck GJ, Greene T, Wang X, Kusek JW, Collins AJ, Levey AS, Menon V: **Fetuin-A is not associated with mortality in chronic kidney disease.** *Kidney Int* 2007, **72**:1394-1399.
94. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM: **Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial.** *JAMA* 2007, **298**:1163-1170.
95. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, Zoungas S, Lambers Heerspink HJ, Chalmers J, Zanchetti A: **Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial.** *J Am Coll Cardiol* 2010, **56**:956-965.
96. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing P: **Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.** *Kidney Int* 2008, **74**:649-654.
97. Jorsal A, Tarnow L, Lajer M, Ek J, Hansen T, Pedersen O, Parving HH: **The PPAR γ 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.** *Mol Genet Metab* 2008, **94**:347-351.
98. Kalra PA, Chrysochou C, Green D, Cheung CM, Khavandi K, Sixt S, Rastan A, Zeller T: **The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease.** *Catheter Cardiovasc Interv* 2010, **75**:1-10.
99. Kellerman QD, Christensen AJ, Baldwin AS, Lawton WJ: **Association between depressive symptoms and mortality risk in chronic kidney disease.** *Health Psychol* 2010, **29**:594-600.
100. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: **Serum phosphate levels and mortality risk among people with chronic kidney disease.** *J Am Soc Nephrol* 2005, **16**:520-528.
101. Khan F, Adelstein E, Saba S: **Implantable cardioverter defibrillators confer survival benefit in patients with renal insufficiency but not in dialysis-dependent patients.** *J Interv Card Electrophysiol* 2010, **28**:117-123.
102. Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R: **Serum potassium and outcomes in CKD: Insights from the RRI-CKD cohort study.** *Clin J Am Soc Nephrol* 2010, **5**:762-769.
103. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: **Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease.** *Kidney Int* 2008, **73**:1296-1302.
104. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: **Paradoxical Association Between Body Mass Index and Mortality in Men With CKD Not Yet on Dialysis.** *Am J Kidney Dis* 2007, **49**:581-591.
105. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: **Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD.** *Nephrol Dial Transplant* 2009, **24**:1232-1237.
106. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: **Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease.** *Clin Nephrol* 2010, **73**:268-275.

107. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K: **Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD.** *Am J Kidney Dis* 2010, **56**:842-851.
108. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K: **Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease.** *Clin J Am Soc Nephrol* 2010, **5**:468-476.
109. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, Kalantar-Zadeh K: **Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure.** *Circulation* 2012, **125**:677-684.
110. Kovesdy CP, Trivedi BK, Anderson JE: **Association of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: A historical prospective cohort study.** *Adv Chronic Kidney Dis* 2006, **13**:183-188.
111. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE: **Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease.** *Nephrol Dial Transplant* 2006, **21**:1257-1262.
112. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE: **Association of anemia with outcomes in men with moderate and severe chronic kidney disease.** *Kidney Int* 2006, **69**:560-564.
113. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K: **Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD.** *Nephrol Dial Transplant* 2010, **25**:3003-3011.
114. Kumar B, Tilea A, Gillespie BW, Zhang X, Kiser M, Eisele G, Finkelstein F, Kotanko P, Levin N, Rajagopalan S, Saran R: **Significance of self-reported sleep quality (SQ) in chronic kidney disease (CKD): The Renal Research Institute (RRI)-CKD study.** *Clin Nephrol* 2010, **73**:104-114.
115. Lambers Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, Cooper M, Grobbee DE, Mancia G, Mogensen CE, et al: **Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease.** *Eur Heart J* 2010, **31**:2888-2896.
116. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, Ferro CJ, Vickery S, Ayrton P, Nair D, et al: **Prediction of ESRD and death among people with CKD: The chronic renal impairment in Birmingham (CRIB) prospective cohort study.** *Am J Kidney Dis* 2010, **56**:1082-1094.
117. Lee PH, Wu VC, Hu FC, Lai CF, Chen YM, Tsai TJ, Wu KD: **Outcomes following dialysis for acute kidney injury among different stages of chronic kidney disease.** *Am J Nephrol* 2011, **34**:95-103.
118. Levin A, Djurdjev O, Beaulieu M, Er L: **Variability and Risk Factors for Kidney Disease Progression and Death Following Attainment of Stage 4 CKD in a Referred Cohort.** *Am J Kidney Dis* 2008, **52**:661-671.
119. Levin A, Djurdjev O, Duncan J, Rosenbaum D, Werb R: **Haemoglobin at time of referral prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes.** *Nephrol Dial Transplant* 2006, **21**:370-377.
120. Li S, Foley RN, Collins AJ: **Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease.** *Int Urol Nephrol* 2005, **37**:395-402.
121. Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G, Kamel S, Massy ZA: **The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.** *Nephrol Dial Transplant* 2010, **25**:2596-2602.
122. Liabeuf S, Barreto DV, Kretschmer A, Barreto FC, Renard C, Andrejak M, Choukroun G, Massy Z: **High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients.** *Atherosclerosis* 2011, **215**:116-124.
123. Lu TM, Chung MY, Lin CC, Hsu CP, Lin SJ: **Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease.** *Clin J Am Soc Nephrol* 2011, **6**:1566-1572.
124. Madero M, Sarnak MJ, Wang X, Sceppa CC, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V: **Body Mass Index and Mortality in CKD.** *Am J Kidney Dis* 2007, **50**:404-411.
125. Meisinger C, Döring A, Löwel H: **Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population.** *Eur Heart J* 2006, **27**:1245-1250.
126. Menon V, Greene T, Pereira AA, Wang X, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: **Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease.** *J Am Soc Nephrol* 2005, **16**:3411-3417.

127. Menon V, Greene T, Pereira AA, Wang X, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: **Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.** *Am J Kidney Dis* 2005, **46**:455-463.
128. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: **C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease.** *Kidney Int* 2005, **68**:766-772.
129. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, et al: **Adiponectin and mortality in patients with chronic kidney disease.** *J Am Soc Nephrol* 2006, **17**:2599-2606.
130. Methven S, MacGregor MS, Traynor JP, Hair M, O'Reilly DSJ, Deighan CJ: **Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD.** *Am J Kidney Dis* 2011, **57**:21-28.
131. Methven S, Traynor JP, Hair MD, St J O'Reilly D, Deighan CJ, MacGregor MS: **Stratifying risk in chronic kidney disease: an observational study of UK guidelines for measuring total proteinuria and albuminuria.** *QJM* 2011, **104**:663-670.
132. Miyamoto T, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P: **Circulating follistatin in patients with chronic kidney disease: Implications for muscle strength, bone mineral density, inflammation, and survival.** *Clin J Am Soc Nephrol* 2011, **6**:1001-1008.
133. Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP: **High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian Type 2 diabetic patients: An 8-year follow-up study.** *Diabet Med* 2007, **24**:1136-1142.
134. Neves PL, Malho A, Cabrita A, Pinho A, Baptista A, Morgado E, Faísca M, Carrasqueira H, Silva AP: **Statins and vitamin D: A friendly association in pre-dialysis patients.** *Int Urol Nephrol* 2010, **42**:173-179.
135. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, et al: **Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.** *Am J Kidney Dis* 2006, **48**:739-751.
136. Obi Y, Kimura T, Nagasawa Y, Yamamoto R, Yasuda K, Sasaki K, Kitamura H, Imai E, Rakugi H, Isaka Y, Hayashi T: **Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort.** *Clin J Am Soc Nephrol* 2010, **5**:1558-1565.
137. Perkins RM, Bucaloiu ID, Kirchner HL, Ashouian N, Hartle JE, Yahya T: **GFR decline and mortality risk among patients with chronic kidney disease.** *Clin J Am Soc Nephrol* 2011, **6**:1879-1886.
138. Ramachandran J, Juneja R, John L, Dutta AK, Chen JW, Woodman RJ, Wigg AJ: **Chronic kidney disease following liver transplantation: A south australian experience.** *Transplant Proc* 2010, **42**:3644-3646.
139. Ramkumar N, Murtaugh MA, Cheung AK, Beddhu S: **Lack of Synergistic Effects of Metabolic Syndrome and Plasma Fibrinogen on Coronary Events and Mortality in Moderate CKD.** *Am J Kidney Dis* 2007, **49**:356-364.
140. Reed B, Helal I, McFann K, Wang W, Yan XD, Schrier RW: **The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.** *Nephrol Dial Transplant* 2012, **27**:2862-2865.
141. Rossing K, Christensen PK, Hovind P, Parving HH: **Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients.** *Diabetologia* 2005, **48**:2241-2247.
142. Sandvik MK, Iversen BM, Irgens LM, Skjaerven R, Leivestad T, Sjøfteland E, Vikse BE: **Are adverse pregnancy outcomes risk factors for development of end-stage renal disease in women with diabetes?** *Nephrol Dial Transplant* 2010, **25**:3600-3607.
143. Schumock GT, Andress D, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K: **Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients.** *Curr Med Res Opin* 2008, **24**:3037-3048.
144. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA: **The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report.** *Clin J Am Soc Nephrol* 2010, **5**:568-575.
145. Scolari F, Ravani P, Pola A, Guerini S, Zubani R, Movilli E, Savoldi S, Malberti F, Maiorca R: **Predictors of renal and patient outcomes in atheroembolic renal disease: A prospective study.** *J Am Soc Nephrol* 2003, **14**:1584-1590.

146. Senevirathna L, Abeysekera T, Nanayakkara S, Chandrajith R, Ratnatunga N, Harada KH, Hitomi T, Komiya T, Muso E, Koizumi A: **Risk factors associated with disease progression and mortality in chronic kidney disease of uncertain etiology: A cohort study in Medawachchiya, Sri Lanka.** *Environ Health Prev Med* 2012, **17**:191-198.
147. Sheng X, Murphy MJ, Macdonald TM, Wei L: **Effectiveness of statins in chronic kidney disease.** *QJM* 2012, **105**:641-648.
148. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M: **Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: A population-based cohort study.** *Arch Intern Med* 2011, **171**:1920-1927.
149. Smith ER, Tomlinson LA, Ford ML, McMahon LP, Rajkumar C, Holt SG: **Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease.** *Hypertension* 2012, **59**:973-978.
150. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, De Zeeuw D, Ivanovich P, Levey AS, Parfrey P, et al: **Erythropoietic response and outcomes in kidney disease and type 2 diabetes.** *N Engl J Med* 2010, **363**:1146-1155.
151. Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S, Hamaguchi K, Nagaya H, Tatematsu M, Kurata K, et al: **Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events.** *Clin Exp Nephrol* 2010, **14**:43-50.
152. Thomas MC, Moran J, Forsblom C, Harjutsalo V, Thorn L, Ahola A, Wadén J, Tolonen N, Saraheimo M, Gordin D, Groop PH: **The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes.** *Diabetes Care* 2011, **34**:861-866.
153. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH: **Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease.** *Nephrology (Carlton)* 2009, **14**:240-246.
154. Turin TC, Coresh J, Tonelli M, Stevens PE, De Jong PE, Farmer CKT, Matsushita K, Hemmelgarn BR: **One-year change in kidney function is associated with an increased mortality risk.** *Am J Nephrol* 2012, **36**:41-49.
155. Uchigata Y, Asao K, Matsushima M, Sato A, Yokoyama H, Otani T, Kasahara T, Takaike H, Okudaira M, Miura J, et al: **Impact on mortality and incidence of end-stage renal disease of education and treatment at a diabetes center among patients with type 1 diabetes: Comparison of two subgroups in the Japanese DERI cohort.** *J Diabetes Complications* 2004, **18**:155-159.
156. Wang Y, Guo X, Li J, Hu D, Zhao D, Ma H, Mou Q, Liu J, Xu Y: **Predictive value of ankle-brachial index to all-cause mortality and cardiovascular mortality in Chinese patients with chronic kidney disease.** *Vasa* 2012, **41**:205-213.
157. Warnock DG, Muntner P, McCullough PA, Zhang X, McClure LA, Zakai N, Cushman M, Newsome BB, Kewalramani R, Steffes MW, et al: **Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.** *Am J Kidney Dis* 2010, **56**:861-871.
158. Weber C, Sigrist M, Romann A, Chiarelli G, Levin A: **Novel biomarkers do not correlate with severity of vascular stiffness in ckd patients with severe co-morbid disease.** *Nephron Clin Pract* 2011, **119**:c261-c268.
159. Weiss JW, Johnson ES, Petrik A, Smith DH, Yang X, Thorp ML: **Systolic blood pressure and mortality among older community-dwelling adults with CKD.** *Am J Kidney Dis* 2010, **56**:1062-1071.
160. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS: **P-cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease.** *Nephrol Dial Transplant* 2011, **26**:938-947.
161. Wu IW, Wang SY, Hsu KH, Lee CC, Sun CY, Tsai CJ, Wu MS: **Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality-a controlled cohort study based on the NKFDOQI guidelines.** *Nephrol Dial Transplant* 2009, **24**:3426-3433.
162. Xue JL, Eggers PW, Agodoa LY, Foley RN, Collins AJ: **Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries.** *J Am Soc Nephrol* 2007, **18**:1299-1306.
163. Yamashita T, Yoshida T, Ogawa T, Tsuchiya K, Nitta K: **Clinical outcomes in patients with chronic kidney disease: A 5-year retrospective cohort study at a University Hospital in Japan.** *Clin Exp Nephrol* 2011, **15**:831-840.
164. Yang JW, Han ST, Song SH, Kim MK, Kim JS, Choi SO, Han BG: **Serum T3 level can predict cardiovascular events and all-cause mortality rates in CKD patients with proteinuria.** *Ren Fail* 2012, **34**:364-372.

165. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, et al: **Vascular health, systemic inflammation and progressive reduction in kidney function; Clinical determinants and impact on cardiovascular outcomes.** *Nephrol Dial Transplant* 2011, **26**:3537-3543.
166. Young BA, Von Korff M, Heckbert SR, Ludman EJ, Rutter C, Lin EHB, Ciechanowski PS, Oliver M, Williams L, Himmelfarb J, Katon WJ: **Association of major depression and mortality in Stage 5 diabetic chronic kidney disease.** *Gen Hosp Psychiatry* 2010, **32**:119-124.
167. Young JM, Terrin N, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V: **Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.** *Clin J Am Soc Nephrol* 2009, **4**:1115-1120.
168. Agarwal R, Bunaye Z, Bekele DM, Light RP: **Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease.** *Am J Nephrol* 2008, **28**:569-575.
169. El-Ghoul B, Elie C, Sqalli T, Jungers P, Daudon M, Grünfeld JP, Lesavre P, Joly D: **Nonprogressive kidney dysfunction and outcomes in older adults with chronic kidney disease.** *J Am Geriatr Soc* 2009, **57**:2217-2223.
170. Eriksen BO, Ingebretsen OC: **The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age.** *Kidney Int* 2006, **69**:375-382.
171. Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA: **Effect of hemoglobin target on progression of kidney disease: A secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.** *Am J Kidney Dis* 2012, **60**:390-401.
172. Newsome BB, McClellan WM, Allison JJ, Eggers PW, Chen SC, Collins AJ, Kiefe CI, Coffey CS, Warnock DG: **Racial Differences in the Competing Risks of Mortality and ESRD After Acute Myocardial Infarction.** *Am J Kidney Dis* 2008, **52**:251-261.
173. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, et al: **Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.** *J Am Soc Nephrol* 2012, **23**:507-515.
174. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: **Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach.** *J Am Soc Nephrol* 2005, **16**:2449-2455.
175. Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L: **Chronic kidney disease and the risk of end-stage renal disease versus death.** *J Gen Intern Med* 2011, **26**:379-385.
176. Derose SF, Rutkowski MP, Levin NW, Liu ILA, Shi JM, Jacobsen SJ, Crooks PW: **Incidence of end-stage renal disease and death among insured African Americans with chronic kidney disease.** *Kidney Int* 2009, **76**:629-637.
177. Gullion CM, Keith DS, Nichols GA, Smith DH: **Impact of Comorbidities on Mortality in Managed Care Patients With CKD.** *Am J Kidney Dis* 2006, **48**:212-220.
178. Nakayama M, Sato T, Sato H, Yamaguchi Y, Obara K, Kurihara I, Sato K, Hotta O, Seino J, Miyata M, et al: **Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: The Gonryo study.** *Clin Exp Nephrol* 2010, **14**:333-339.
179. Rucker D, Hemmelgarn BR, Lin M, Manns BJ, Klarenbach SW, Ayyalasomayajula B, James MT, Bello A, Gordon D, Jindal KK, Tonelli M: **Quality of care and mortality are worse in chronic kidney disease patients living in remote areas.** *Kidney Int* 2011, **79**:210-217.
180. Wang F, Zhang L, Zuo L, Liu L, Wang H: **Mortality and renal function decline among a community-based Chinese population with normal or mildly impaired renal function.** *Nephrol Dial Transplant* 2011, **26**:2847-2852.
181. Busch M, Fleck C, Wolf G, Stein G: **Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - Possible candidates for paradoxical epidemiology?** *Amino Acids* 2006, **30**:225-232.
182. Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, Sarnak MJ: **Waist-to-Hip Ratio and Body Mass Index as Risk Factors for Cardiovascular Events in CKD.** *Am J Kidney Dis* 2008, **52**:49-57.
183. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH: **Bone markers predict cardiovascular events in chronic kidney disease.** *J Bone Miner Res* 2008, **23**:1850-1858.
184. Obermayr RP, Temml C, Gutjahr G, Kainz A, Klauser-Braun R, Függer R, Oberbauer R: **Body mass index modifies the risk of cardiovascular death in proteinuric chronic kidney disease.** *Nephrol Dial Transplant* 2009, **24**:2421-2428.

185. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: **Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors.** *JAMA* 2005, **293**:1737-1745.
186. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, Martins D, Adler SG, Norris KC: **Chronic kidney disease, hypovitaminosis D, and mortality in the United States.** *Kidney Int* 2009, **76**:977-983.
187. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, et al: **Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria.** *Kidney Int Suppl* 2004, **66**:S50-S55.
188. Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA, Coresh J: **Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.** *Am J Kidney Dis* 2012, **59**:653-662.
189. Baek SD, Baek CH, Kim JS, Kim SM, Kim JH, Kim SB: **Does stage III chronic kidney disease always progress to end-stage renal disease? A ten-year follow-up study.** *Scand J Urol Nephrol* 2012, **46**:232-238.
190. Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G: **The Advanced Glycation End Product N ε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension.** *Am J Kidney Dis* 2006, **48**:571-579.
191. Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, Saglam M, Stylianou K, Yaman H, Taslipinar A, et al: **Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.** *Clin J Am Soc Nephrol* 2012, **7**:207-215.
192. Chen FA, Yang CY, Yang WC, Chen JY, Ng YY, Li SY, Liu WS, Cheng ST, Wang YJ, Lin CC: **Ankle-brachial index is a powerful predictor of renal outcome and cardiovascular events in patients with chronic kidney disease.** *ScientificWorldJournal* 2012, **2012**.
193. Meijers BKI, Claes K, Bammens B, De Loo H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P: **p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.** *Clin J Am Soc Nephrol* 2010, **5**:1182-1189.
194. Peralta CA, Shlipak MG, Fan D, Ordoñez J, Lash JP, Chertow GM, Go AS: **Risks for end-stage renal disease, cardiovascular events, and death in hispanic versus non-hispanic white adults with chronic kidney disease.** *J Am Soc Nephrol* 2006, **17**:2892-2899.
195. Sakuma M, Nakamura M, Tanaka F, Onoda T, Itai K, Tanno K, Ohsawa M, Sakata K, Yoshida Y, Kawamura K, et al: **Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population.** *Circ J* 2010, **74**:792-797.
196. Sasso FC, Chiodini P, Carbonara O, De Nicola L, Conte G, Salvatore T, Nasti R, Marfella R, Gallo C, Signoriello S, et al: **High cardiovascular risk in patients with Type 2 diabetic nephropathy: The predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study.** *Nephrol Dial Transplant* 2012, **27**:2269-2274.
197. Shepherd J, Kastelein JJP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK: **Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.** *Mayo Clin Proc* 2008, **83**:870-879.
198. Weiner DE, Krassilnikova M, Tighiouart H, Salem DN, Levey AS, Sarnak MJ: **CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: A cohort study.** *BMC Nephrol* 2009, **10**.
199. Zoungas S, Cameron JD, Kerr PG, Wolfe R, Muske C, McNeil JJ, McGrath BP: **Association of Carotid Intima-Medial Thickness and Indices of Arterial Stiffness With Cardiovascular Disease Outcomes in CKD.** *Am J Kidney Dis* 2007, **50**:622-630.
200. Alarcón GS, McGwin Jr G, Petri M, Ramsey-Goldman R, Fessler BJ, Vilá LM, Edberg JC, Reveille JD, Kimberly RP: **Time to renal disease and end-stage renal disease in PROFILE: A multiethnic lupus cohort.** *PLoS Med* 2006, **3**:1949-1956.
201. Chan JCN, Wat N, So WY, Lam KSL, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, et al: **Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients with Type 2 Diabetes: An Asian perspective from the RENAAL study.** *Diabetes Care* 2004, **27**:874-879.
202. Chandra P, Sands RL, Gillespie BW, Levin NW, Kotanko P, Kiser M, Finkelstein F, Hinderliter A, Pop-Busui R, Rajagopalan S, Saran R: **Predictors of heart rate variability and its prognostic significance in chronic kidney disease.** *Nephrol Dial Transplant* 2012, **27**:700-709.
203. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM: **Racial differences in end-stage renal disease rates in HIV infection versus diabetes.** *J Am Soc Nephrol* 2007, **18**:2968-2974.
204. Conley J, Olafsson A, Djamali A: **Do statins delay the incidence of ESRD in diabetic patients with moderate CKD?** *J Nephrol* 2010, **23**:321-327.

205. Eijkelkamp WBA, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, De Zeeuw D: **Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial.** *J Am Soc Nephrol* 2007, **18**:1540-1546.
206. Gansevoort RT, Matsushita K, Van Der Velde M, Astor BC, Woodward M, Levey AS, Jong PED, Coresh J: **Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.** *Kidney Int* 2011, **80**:93-104.
207. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: **Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.** *Am J Kidney Dis* 2004, **44**:642-650.
208. Iseki K, Tozawa M, Ikemiya Y, Kinjo K, Iseki C, Takishita S: **Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort.** *Clin Exp Nephrol* 2005, **9**:46-52.
209. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenti P, Marcantoni C, Becker G, Shahinfar S, de Jong PE, et al: **The rate of progression of renal disease may not be slower in women compared with men: A patient-level meta-analysis.** *Nephrol Dial Transplant* 2003, **18**:2047-2053.
210. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG: **Risk factors for ESRD in HIV-infected individuals: Traditional and HIV-related factors.** *Am J Kidney Dis* 2012, **59**:628-635.
211. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F: **Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: The Mild to Moderate Kidney Disease Study.** *Kidney Int* 2007, **71**:1279-1286.
212. Komatsu H, Fujimoto S, Sato Y, Hara S, Yamada K, Morita S, Eto T: **"Point of no return (PNR)" in progressive IgA nephropathy: Significance of blood pressure and proteinuria management up to PNR.** *J Nephrol* 2005, **18**:690-695.
213. Kop WJ, Seliger SL, Fink JC, Katz R, Odden MC, Fried LF, Rifkin DE, Sarnak MJ, Gottdiener JS: **Longitudinal association of depressive symptoms with rapid kidney function decline and adverse clinical renal disease outcomes.** *Clin J Am Soc Nephrol* 2011, **6**:834-844.
214. Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY: **Analgesic use and the risk for progression of chronic kidney disease.** *Pharmacoepidemiol Drug Saf* 2010, **19**:745-751.
215. Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, Collins AJ, Kopple JD: **Effect of Dietary Protein Restriction on the Progression of Kidney Disease: Long-Term Follow-Up of the Modification of Diet in Renal Disease (MDRD) Study.** *Am J Kidney Dis* 2006, **48**:879-888.
216. Liu M, Shi S, Senthilnathan S, Yu J, Wu E, Bergmann C, Zerres K, Bogdanova N, Coto E, Deltas C, et al: **Genetic variation of DKK3 may modify renal disease severity in ADPKD.** *J Am Soc Nephrol* 2010, **21**:1510-1520.
217. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD: **Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.** *Kidney Int* 2004, **66**:1131-1138.
218. Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, Ito S: **Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: The Gonryo study.** *Hypertens Res* 2011, **34**:1106-1110.
219. Omae K, Ogawa T, Nitta K: **Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.** *Heart Vessels* 2010, **25**:203-208.
220. Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P, Cannella G: **Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease?** *Nephrol Dial Transplant* 2011, **26**:670-677.
221. Radican L, Wartenberg D, Rhoads GG, Schneider D, Wedeen R, Stewart P, Blair A: **A retrospective occupational cohort study of end-stage renal disease in aircraft workers exposed to trichloroethylene and other hydrocarbons.** *J Occup Environ Med* 2006, **48**:1-12.
222. Reed BY, McFann K, Reza Bekheirnia M, Nobkthaghghi N, Masoumi A, Johnson AM, Abdollah Shamshiraz A, Kelleher CL, Schrier RW: **Variation in Age at ESRD in Autosomal Dominant Polycystic Kidney Disease.** *Am J Kidney Dis* 2008, **51**:173-183.
223. Roblin DW, Khoury A, Pisanelli W, Dahar W, Roth M: **Risk for Incident Renal Dialysis in a Managed Care Population.** *Am J Kidney Dis* 2006, **48**:205-211.

224. Ruggenenti P, Perticucci E, Cravedi P, Gambarà V, Costantini M, Sharma SK, Perna A, Remuzzi G: **Role of remission clinics in the longitudinal treatment of CKD.** *J Am Soc Nephrol* 2008, **19**:1213-1224.
225. Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, Kawabata H, Niihata K, Okada N, Isaka Y, et al: **Hypomagnesemia in type 2 diabetic nephropathy: A novel predictor of end-stage renal disease.** *Diabetes Care* 2012, **35**:1591-1597.
226. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS: **The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study.** *Ann Intern Med* 2005, **142**:342-351.
227. Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM: **Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study.** *Kidney Int Suppl* 2002, **62**:S64-S67.
228. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: **A predictive model for progression of chronic kidney disease to kidney failure.** *JAMA* 2011, **305**:1553-1559.
229. Tazón-Vega B, Vilardell M, Pérez-Oller L, Ars E, Ruiz P, Devuyt O, Lens X, Fernández-Llama P, Ballarín J, Torra R: **Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1.** *Nephrol Dial Transplant* 2007, **22**:1567-1577.
230. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare AM: **Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease.** *Arch Intern Med* 2007, **167**:1271-1276.
231. Welander A, Prütz KG, Foröd M, Ludvigsson JF: **Increased risk of end-stage renal disease in individuals with coeliac disease.** *Gut* 2012, **61**:64-68.
232. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, et al: **Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial.** *JAMA* 2002, **288**:2421-2431.
233. Okonogi H, Utsunomiya Y, Miyazaki Y, Koike K, Hirano K, Tsuboi N, Suzuki T, Hara Y, Ogura M, Hosoya T, Kawamura T: **A predictive clinical grading system for immunoglobulin a nephropathy by combining proteinuria and estimated glomerular filtration rate.** *Nephron Clin Pract* 2011, **118**:c292-c300.
234. Banerjee D, Brincat S, Gregson H, Contreras G, Streather C, Oliveira D, Nelson S: **Pulse pressure and inhibition of renin-angiotensin system in chronic kidney disease.** *Nephrol Dial Transplant* 2006, **21**:975-978.
235. Berthoux FC, Berthoux P, Mariat C, Thibaudin L, Afiani A, Linossier MT: **CC-chemokine receptor five gene polymorphism in primary IgA nephropathy: The 32 bp deletion allele is associated with late progression to end-stage renal failure with dialysis.** *Kidney Int* 2006, **69**:565-572.
236. Evans M, Foröd CM, Nise G, Bellocco R, Nyrén O, Elinder CG: **Occupational Lead Exposure and Severe CKD: A Population-Based Case-Control and Prospective Observational Cohort Study in Sweden.** *Am J Kidney Dis* 2010, **55**:497-506.
237. Jones C, Roderick P, Harris S, Rogerson M: **An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD.** *Am J Kidney Dis* 2006, **47**:103-114.
238. Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P, Dicks E, Parfrey P, Torra R, San-Millan JL, et al: **Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease.** *J Am Soc Nephrol* 2003, **14**:1164-1174.
239. Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L: **Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.** *Clin J Am Soc Nephrol* 2009, **4**:552-559.
240. Nouredine LA, Usman SA, Yu Z, Moorthi RN, Moe SM: **Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis.** *Am J Nephrol* 2010, **32**:311-316.
241. Rabbani MA, Ali SS, Murtaza G, Ahmad B, Maria Q, Siddiqui BK, Shah SMA, Ahmad A: **Clinical presentation and outcome of Autosomal Dominant Polycystic Kidney Disease in Pakistan: A single center experience.** *J Pak Med Assoc* 2008, **58**:305-309.
242. Roshanravan B, Khatri M, Robinson-Cohen C, Levin G, Patel KV, de Boer IH, Seliger S, Ruzinski J, Himmelfarb J, Kestenbaum B: **A Prospective Study of Frailty in Nephrology-Referred Patients With CKD.** *Am J Kidney Dis* 2012.
243. Smith DH, Johnson ES, Thorp ML, Yang X, Neil N: **Hyperparathyroidism in chronic kidney disease: A retrospective cohort study of costs and outcomes.** *J Bone Miner Metab* 2009, **27**:287-294.

244. Tsai YC, Hung CC, Hwang SJ, Wang SL, Hsiao SM, Lin MY, Kung LF, Hsiao PN, Chen HC: **Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease.** *Nephrol Dial Transplant* 2010, **25**:1621-1626.
245. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jong-van den Berg LTW: **The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study.** *Nephrol Dial Transplant* 2006, **21**:3106-3114.
246. Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY, Wu KD: **Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly.** *J Clin Endocrinol Metab* 2012, **97**:1268-1276.
247. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T: **IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.** *J Am Soc Nephrol* 2007, **18**:1880-1888.
248. Goicoechea M, De Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J: **Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.** *Clin J Am Soc Nephrol* 2010, **5**:1388-1393.
249. Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK, He J: **Effect of Blood Pressure on Early Decline in Kidney Function among Hypertensive Men.** *Hypertension* 2003, **42**:1144-1149.
250. Asrani SK, Buchanan P, Pinsky B, Rey LR, Schnitzler M, Kanwal F: **Lack of Association Between Hepatitis C Infection and Chronic Kidney Disease.** *Clin Gastroenterol Hepatol* 2010, **8**:79-84.
251. Bomback AS, Katz R, He K, Shoham DA, Burke GL, Klemmer PJ: **Sugar-sweetened beverage consumption and the progression of chronic kidney disease in the Multi-Ethnic Study of Atherosclerosis (MESA).** *Am J Clin Nutr* 2009, **90**:1172-1178.
252. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman A: **Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals.** *J Am Soc Nephrol* 2004, **15**:3184-3191.
253. Fried LF, Katz R, Cushman M, Sarnak M, Shlipak MG, Kuller L, Newman AB: **Change in cardiovascular risk factors with progression of kidney disease.** *Am J Nephrol* 2009, **29**:334-341.
254. Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S: **Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis.** *Nephrol Dial Transplant* 2010, **25**:3948-3956.
255. Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D, Curhan GC: **The Impact of Protein Intake on Renal Function Decline in Women with Normal Renal Function or Mild Renal Insufficiency.** *Ann Intern Med* 2003, **138**:460-467+I451.
256. Orth SR, Schroeder T, Ritz E, Ferrari P: **Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus.** *Nephrol Dial Transplant* 2005, **20**:2414-2419.
257. White SL, Polkinghorne KR, Cass A, Shaw JE, Atkins RC, Chadban SJ: **Alcohol consumption and 5-year onset of chronic kidney disease: The AusDiab study.** *Nephrol Dial Transplant* 2009, **24**:2464-2472.
258. Hanai K, Babazono T, Yoshida N, Nyumura I, Toya K, Hayashi T, Bouchi R, Tanaka N, Ishii A, Iwamoto Y: **Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients.** *Nephrol Dial Transplant* 2012, **27**:1070-1075.
259. LaMattina JC, Foley DP, Mezrich JD, Fernandez LA, Vidyasagar V, D'Alessandro AM, Musat AI, Samaniego-Picota MD, Pascual J, Alejandro MDR, et al: **Chronic kidney disease stage progression in liver transplant recipients.** *Clin J Am Soc Nephrol* 2011, **6**:1851-1857.
260. Palmas W, Pickering T, Eimicke JP, Moran A, Teresi J, Schwartz JE, Field L, Weinstock RS, Shea S: **Value of Ambulatory Arterial Stiffness Index and 24-h Pulse Pressure to Predict Progression of Albuminuria in Elderly People With Diabetes Mellitus.** *Am J Hypertens* 2007, **20**:493-500.
261. Van Pottelbergh G, Bartholomeeusen S, Buntinx F, Degryse J: **The evolution of renal function and the incidence of end-stage renal disease in patients aged ≥ 50 years.** *Nephrol Dial Transplant* 2012, **27**:2297-2303.
262. Cummings DM, Larsen LC, Doherty L, Lea CS, Holbert D: **Glycemic control patterns and kidney disease progression among primary care patients with diabetes mellitus.** *J Am Board Fam Med* 2011, **24**:391-398.

263. Iwasaki M, Taylor GW, Nesse W, Vissink A, Yoshihara A, Miyazaki H: **Periodontal disease and decreased kidney function in Japanese elderly.** *Am J Kidney Dis* 2012, **59**:202-209.
264. Meguro S, Shighihara T, Kabeya Y, Tomita M, Atsumi Y: **Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects.** *Intern Med* 2009, **48**:657-663.
265. Nishiyama K, Tanaka Y, Nakajima K, Mokubo A, Atsumi Y, Matsuoka K, Watada H, Hirose T, Nomiyama T, Maeda S, Kawamori R: **Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 (+78G/A: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: A 10-year longitudinal study.** *Diabetologia* 2005, **48**:1335-1338.
266. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, Cardoso C, Noël LH, Guérin AP, London GM, Jungers P: **Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers.** *Kidney Int* 2004, **66**:1606-1612.
267. Okada T, Matsumoto H, Nagaoka Y, Nakao T: **Association of home blood pressure variability with progression of chronic kidney disease.** *Blood Press Monit* 2012, **17**:1-7.
268. Szczech LA, Gange SJ, Van der Horst C, Bartlett JA, Young M, Cohen MH, Anastos K, Klassen PS, Svetkey LP: **Predictors of proteinuria and renal failure among women with HIV infection.** *Kidney Int* 2002, **61**:195-202.
269. Yamada H, Suga N, Maeda K, Kimura Y, Miura N, Futenma A, Imai H: **Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients: A retrospective, "real-world" comparative study.** *Arzneimittelforschung* 2010, **60**:64-70.
270. Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS, Yoon KH, Cha BY, Lee KW, Son HY: **Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria.** *Diabetes Care* 2005, **28**:1718-1723.
271. Agarwal R, Light RP: **Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease.** *Clin J Am Soc Nephrol* 2011, **6**:1393-1399.
272. Boes E, Fliser D, Ritz E, König P, Lhotta K, Mann JFE, Müller GA, Neyer U, Riegel W, Riegler P, Kronenberg F: **Apolipoprotein A-IV predicts progression of chronic kidney disease: The mild to moderate kidney disease study.** *J Am Soc Nephrol* 2006, **17**:528-536.
273. Chen Y, Salem RM, Rao F, Fung MM, Bhatnagar V, Pandey B, Mahata M, Waalen J, Nievergelt CM, Lipkowitz MS, et al: **Common charge-shift mutation Glu65Lys in K + channel β 1-subunit KCNMB1: Pleiotropic consequences for glomerular filtration rate and progressive renal disease.** *Am J Nephrol* 2010, **32**:414-424.
274. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, Von Eckardstein A, Haltmayer M, Kronenberg F: **Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: The MMKD Study.** *Kidney Int* 2009, **75**:408-414.
275. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F: **Fibroblast Growth Factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) study.** *J Am Soc Nephrol* 2007, **18**:2601-2608.
276. Goyal A, Crook ED: **Thiazolidinediones and progression of renal disease in patients with diabetes.** *J Investig Med* 2006, **54**:56-61.
277. Hunsicker LG, Atkins RC, Lewis JB, Braden G, Champion De Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ: **Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.** *Kidney Int Suppl* 2004, **66**:S99-S101.
278. Hwang HS, Kim BS, Shin YS, Yoon HE, Song JC, Choi BS, Park CW, Yang CW, Kim YS, Bang BK: **Predictors for progression in immunoglobulin A nephropathy with significant proteinuria.** *Nephrology (Carlton)* 2010, **15**:236-241.
279. Jacob S, Héry M, Protois JC, Rossert J, Stengel B: **Effect of organic solvent exposure on chronic kidney disease progression: The GN-PROGRESS cohort study.** *J Am Soc Nephrol* 2007, **18**:274-281.
280. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, De Jong PE, De Zeeuw D, Shahinfar S, Toto R, Levey AS: **Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition. A Patient-Level Meta-Analysis.** *Ann Intern Med* 2003, **139**:244-252+I236.
281. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becicer G, Perrone RD, Levey AS: **The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.** *Kidney Int* 2005, **67**:265-271.

282. Moon SJ, Bae KS, Park HC, Kim JK, Park JT, Lee JE, Rim SJ, Ha SK: **The effect of anemia and left ventricular geometric patterns on renal disease progression in type 2 diabetic nephropathy.** *J Nephrol* 2011, **24**:50-59.
283. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M: **Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy (Retraction in: American Journal of Nephrology (2009) 30:6 (563)).** *Am J Nephrol* 2004, **24**:543-548.
284. Okada T, Nagao T, Matsumoto H, Nagaoka Y, Wada T, Nakao T: **Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria.** *Nephrology (Carlton)* 2012, **17**:68-75.
285. Peters HPE, Waanders F, Meijer E, Van Den Brand J, Steenbergen EJ, Van Goor H, Wetzels JFM: **High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.** *Nephrol Dial Transplant* 2011, **26**:3581-3588.
286. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP: **Association of disorders in mineral metabolism with progression of chronic kidney disease.** *Clin J Am Soc Nephrol* 2006, **1**:825-831.
287. Soares CM, Diniz JSS, Lima EM, Oliveira GR, Canhestro MR, Colosimo EA, E Silva ACS, Oliveira EA: **Predictive factors of progression to chronic kidney disease stage 5 in a predialysis interdisciplinary programme.** *Nephrol Dial Transplant* 2009, **24**:848-855.
288. Staples AO, Greenbaum LA, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Wong CS: **Association between clinical risk factors and progression of chronic kidney disease in children.** *Clin J Am Soc Nephrol* 2010, **5**:2172-2179.
289. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F: **Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study.** *Exp Gerontol* 2008, **43**:347-352.
290. Yang XL, So WY, Kong APS, Clarke P, Ho CS, Lam CWK, Ng MHL, Lyu RR, Yin DD, Chow CC, et al: **End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.** *Diabetologia* 2006, **49**:2299-2308.
291. Yu CC, Lin JL, Lin-Tan DT: **Environmental Exposure to Lead and Progression of Chronic Renal Diseases: A Four-Year Prospective Longitudinal Study.** *J Am Soc Nephrol* 2004, **15**:1016-1022.
292. Scialla JJ, Appel LJ, Astor BC, Miller Iii ER, Beddhu S, Woodward M, Parekh RS, Anderson CAM: **Net endogenous acid production is associated with a faster decline in GFR in African Americans.** *Kidney Int* 2012, **82**:106-112.
293. Kim SB, Kwon S, Lee SK, Park JS: **Association of Atherosclerotic Coronary Artery Disease and Pulse Pressure with Renal Disease Progression.** *Ren Fail* 2003, **25**:1019-1027.
294. Caplin B, Nitsch D, Gill H, Hoefield R, Blackwell S, MacKenzie D, Cooper JA, Middleton RJ, Talmud PJ, Veitch P, et al: **Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.** *Kidney Int* 2010, **77**:459-467.
295. Caron M, Hudson M, Baron M, Nessim S, Steele R, Pope J, Markland J, Robinson D, Jones N, Khalidi N, et al: **Longitudinal study of renal function in systemic sclerosis.** *J Rheumatol* 2012, **39**:1829-1834.
296. Elung-Jensen T, Strandgaard S, Kamper AL: **Longitudinal observations on circadian blood pressure variation in chronic kidney disease stages 3-5.** *Nephrol Dial Transplant* 2008, **23**:2873-2878.
297. Fung MM, Chen Y, Lipkowitz MS, Salem RM, Bhatnagar V, Mahata M, Nievergelt CM, Rao F, Mahata SK, Schork NJ, et al: **Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis.** *Nephrol Dial Transplant* 2009, **24**:3677-3686.
298. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC: **The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era.** *Antivir Ther* 2009, **14**:543-549.
299. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS: **Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience.** *Clin J Am Soc Nephrol* 2011, **6**:2499-2507.
300. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, Smurzynski M, Albert JM: **Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.** *AIDS* 2008, **22**:481-487.
301. Kobayashi M, Hirawa N, Morita S, Yatsu K, Kobayashi Y, Yamamoto Y, Saka S, Toya Y, Yasuda G, Umemura S: **Silent brain infarction and rapid decline of kidney function in patients with CKD: A prospective cohort study.** *Am J Kidney Dis* 2010, **56**:468-476.

302. Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE: **Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.** *Kidney Int* 2010, **78**:303-309.
303. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E: **Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.** *J Hepatol* 2011, **55**:1235-1240.
304. Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, Gerstoft J, Obel N: **Renal function and incidence of chronic kidney disease in HIV patients: A Danish cohort study.** *Scand J Infect Dis* 2012, **44**:689-696.
305. Von Känel R, Mausbach BT, Dimsdale JE, Mills PJ, Patterson TL, Ancoli-Israel S, Ziegler MG, Roepke SK, Chattillion EA, Allison M, Grant I: **Effect of chronic dementia caregiving and major transitions in the caregiving situation on kidney function: A longitudinal study.** *Psychosom Med* 2012, **74**:214-220.
306. Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M, Feldman H, Gassman J, Lea J, Kopple J, et al: **Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease.** *J Am Soc Nephrol* 2006, **17**:2900-2909.
307. Zhang P, Song P, Qu A, Greene T: **Efficient estimation for patient-specific rates of disease progression using nonnormal linear mixed models.** *Biometrics* 2008, **64**:29-38.
308. Liu M, Ying Z: **Joint analysis of longitudinal data with informative right censoring.** *Biometrics* 2007, **63**:363-371+633.
309. Xu L, Shao J: **Estimation in longitudinal or panel data models with random-effect-based missing responses.** *Biometrics* 2009, **65**:1175-1183.
310. Nanayakkara PWB, Van Guldener C, Ter Wee PM, Scheffer PG, Van Ittersum FJ, Twisk JW, Teerlink T, Van Dorp W, Stehouwer CDA: **Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: Results from the anti-oxidant therapy in chronic renal insufficiency (ATIC) study.** *Arch Intern Med* 2007, **167**:1262-1270.
311. Liu M, Lu W: **A semiparametric marginalized model for longitudinal data with informative dropout.** *J Probab Stat* 2012.
312. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecker T, Tison L: **Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study.** *J Am Soc Nephrol* 2002, **13**:1733-1739.
313. Szeto CC, Chow KM, Kwan BCH, Chung KY, Leung CB, Li PKT: **Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled Trial.** *Am J Kidney Dis* 2008, **51**:724-731.
314. Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, Cohen MH, Peters MG, Golub ET, Szczech L: **Hepatitis C Seropositivity and Kidney Function Decline Among Women With HIV: Data From the Women's Interagency HIV Study.** *Am J Kidney Dis* 2009, **54**:43-50.
315. Camilla R, Brachemi S, Pichette V, Cartier P, Laforest-Renald A, MacRae T, Madore F, Troyanov S: **Urinary monocyte chemotactic protein 1: Marker of renal function decline in diabetic and nondiabetic proteinuric renal disease.** *J Nephrol* 2011, **24**:60-67.
316. De Boer IH, Katz R, Fried LF, Ix JH, Luchsinger J, Sarnak MJ, Shlipak MG, Siscovick DS, Kestenbaum B: **Obesity and Change in Estimated GFR Among Older Adults.** *Am J Kidney Dis* 2009, **54**:1043-1051.
317. Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW: **Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study.** *Am J Kidney Dis* 2002, **39**:1127-1134.
318. Keller C, Katz R, Sarnak MJ, Fried LF, Kestenbaum B, Cushman M, Shlipak MG: **Inflammatory biomarkers and decline in kidney function in the elderly: The Cardiovascular Health Study.** *Nephrol Dial Transplant* 2010, **25**:119-124.
319. Khedr A, Khedr E, House AA: **Body Mass Index and the Risk of Progression of Chronic Kidney Disease.** *J Ren Nutr* 2011, **21**:455-461.
320. Lane C, Ashcroft A, Bothamley G, Yaqoob MM, Fan SLS: **Accelerated decline of GFR in diabetic nephropathy predicted by interferon release assay to tuberculosis antigens.** *Nephron Clin Pract* 2011, **117**:c266-c269.
321. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG: **HIV viremia and changes in kidney function.** *AIDS* 2009, **23**:1089-1096.
322. Menon V, Katz R, Mukamal K, Kestenbaum B, De Boer IH, Siscovick DS, Sarnak MJ, Shlipak MG: **Alcohol consumption and kidney function decline in the elderly.** *Nephrol Dial Transplant* 2010, **25**:3301-3307.

323. Othman M, Kawar B, El Nahas AM: **Influence of obesity on progression of non-diabetic chronic kidney disease: A retrospective cohort study.** *Nephron Clin Pract* 2009, **113**:c16-c23.
324. Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y: **Self-measured systolic blood pressure in the morning is a strong indicator of decline of renal function in hypertensive patients with non-diabetic chronic renal insufficiency.** *Clin Exp Hypertens* 2002, **24**:249-260.
325. Tokiwa S, Muto S, China T, Horie S: **The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease.** *Clin Exp Nephrol* 2011, **15**:539-545.
326. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC: **Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.** *Am J Kidney Dis* 2004, **44**:832-839.
327. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC: **Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.** *J Am Soc Nephrol* 2003, **14**:1605-1613.
328. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G: **Biomarkers of inflammation and progression of chronic kidney disease.** *Kidney Int* 2005, **68**:237-245.
329. Yokoyama H, Kanno S, Takahashi S, Yamada D, Honjo J, Saito K, Sone H, Haneda M: **Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes.** *Nephrol Dial Transplant* 2011, **26**:2924-2930.
330. Yokoyama H, Kanno S, Takahashi S, Yamada D, Itoh H, Saito K, Sone H, Haneda M: **Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension.** *Clin J Am Soc Nephrol* 2009, **4**:1432-1440.
331. Yoshida T, Takei T, Shirota S, Tsukada M, Sugiura H, Itabashi M, Ogawa T, Uchida K, Tsuchiya K, Nitta K: **Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population.** *Intern Med* 2008, **47**:1859-1864.
332. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR: **NSAID Use and Progression of Chronic Kidney Disease.** *Am J Med* 2007, **120**:e281-e287.
333. Lee YT, Chiu HC, Huang CT, Su HM, Wang CL, Lin TH, Voon WC, Chen HC, Lai WT, Sheu SH: **The A1166C polymorphism of angiotensin II type 1 receptor as a predictor of renal function decline over 4 years follow-up in an apparently healthy Chinese population.** *Clin Nephrol* 2009, **72**:457-467.
334. Lee YT, Chiu HC, Su HM, Voon WC, Lin TH, Lai WT, Sheu SH: **The D allele of angiotensin-converting enzyme polymorphism as a predictor of renal function decline over 4 years in an apparently healthy Chinese population aged 60 and older.** *J Am Geriatr Soc* 2008, **56**:718-723.
335. Arulkumaran N, Diwakar R, Tahir Z, Mohamed M, Kaski JC, Banerjee D: **Pulse pressure and progression of chronic kidney disease.** *J Nephrol* 2010, **23**:189-193.
336. Bastian HM, Alarcón GS, Roseman JM, McGwin Jr G, Vilá LM, Fessler BJ, Reveille JD, Fernández M, Andrade R, Sanchez ML, et al: **Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: Factors predictive of new or worsening proteinuria.** *Rheumatology (Oxford)* 2007, **46**:683-689.
337. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M: **Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.** *Clin J Am Soc Nephrol* 2009, **4**:337-344.
338. Bruno G, Biggeri A, Merletti F, Barger G, Ferrero S, Pagano G, Perin PC: **Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: A 10-year prospective study.** *Diabetes Care* 2003, **26**:2353-2358.
339. Buck J, Baker R, Cannaby AM, Nicholson S, Peters J, Warwick G: **Why do patients known to renal services still undergo urgent dialysis initiation? A cross-sectional survey.** *Nephrol Dial Transplant* 2007, **22**:3240-3245.
340. Daratha KB, Short RA, Corbett CF, Ring ME, Alicic R, Choka R, Tuttle KR: **Risks of subsequent hospitalization and death in patients with kidney disease.** *Clin J Am Soc Nephrol* 2012, **7**:409-416.
341. Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puéchal X, Lachmann HJ, et al: **Eprodisate for the treatment of renal disease in AA amyloidosis.** *N Engl J Med* 2007, **356**:2349-2360.
342. Komatsu H, Fujimoto S, Kikuchi M, Sato Y, Kitamura K: **Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease.** *Ren Fail* 2012, **34**:448-453.

343. Lee CC, Sun CY, Wu IW, Wang SY, Wu MS: **Metabolic syndrome loses its predictive power in late-stage chronic kidney disease progression - A paradoxical phenomenon.** *Clin Nephrol* 2011, **75**:141-149.
344. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordóñez JD, Hsu CY: **Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease.** *Kidney Int* 2009, **76**:893-899.
345. Morita S, Fukuhara S, Akizawa T, Asano Y, Koshikawa S, Koide K, Kurokawa K: **Prognostic factors for a composite end-point of renal outcomes in patients with chronic kidney disease.** *Ther Apher Dial* 2006, **10**:72-77.
346. Panizo N, Goicoechea M, de Vinuesa SG, Arroyo D, Yuste C, Rincón A, Verdalles U, Ruiz-Caro C, Quiroga B, Luño J: **Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.** *Nefrologia* 2012, **32**:197-205.
347. Sezer S, Karakan S, Acar NO: **Association of conicity index and renal progression in pre-dialysis chronic kidney disease.** *Ren Fail* 2012, **34**:165-170.
348. Sugiura T, Wada A: **Resistive index predicts renal prognosis in chronic kidney disease.** *Nephrol Dial Transplant* 2009, **24**:2780-2785.
349. Taskapan H, Tam P, Au V, Chow S, Fung J, Nagai G, Roscoe J, Ng P, Sikaneta T, Ting R, Oreopoulos DG: **Improvement in eGFR in patients with chronic kidney disease attending a nephrology clinic.** *Int Urol Nephrol* 2008, **40**:841-848.
350. Zhang AH, Tam P, Leblanc D, Zhong H, Chan CT, Bargman JM, Oreopoulos DG: **Natural history of CKD stage 4 and 5 patients following referral to renal management clinic.** *Int Urol Nephrol* 2009, **41**:977-982.